Lv2
118 积分 2025-07-12 加入
Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
17小时前
待确认
SDC1(+) CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers
19小时前
已完结
Identification of a novel alternative splicing isoform of the Hippo kinase STK3/MST2 with impaired kinase and cell growth suppressing activities
5天前
已完结
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges
2个月前
已完结
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
2个月前
已完结
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
2个月前
已完结
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
3个月前
已完结
Clinical and translational advances in ovarian cancer therapy
3个月前
已完结
Global epidemiology of epithelial ovarian cancer
3个月前
已完结
Large-scale proteomic analyses of incident Parkinson’s disease reveal new pathophysiological insights and potential biomarkers
1年前
已完结
皖公网安备34019202002308
